TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Parallel Group, Open-label, Active Controlled, Multicenter Phase III Trial of Patupilone (EPO906) Versus Pegylated Liposomal Doxorubicin in Taxane/Platinum Refractory/Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian or Primary Peritoneal Cancer
Brief Summary: The objective of this study is to assess the safety and efficacy of patupilone compared to pegylated liposomal doxorubicin. Additionally, this study will assess the ability of patupilone to extend the survival time and potential beneficial effects in women who have nonresponsive or recurrent ovarian, primary fallopian, or primary peritoneal cancer.


Options:
A: Arm Label: Tivozanib; Type: EXPERIMENTAL; Interventions: Drug: Tivozanib | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Tivozanib; Assigned to Arm(s): Tivozanib
B: Arm Label: Patupilone; Type: EXPERIMENTAL; Interventions: Drug: EPO906 (Patupilone) | Arm Label: doxorubicin; Type: ACTIVE_COMPARATOR; Interventions: Drug: doxorubicin | Intervention Type: DRUG; Name: EPO906 (Patupilone); Assigned to Arm(s): Patupilone | Intervention Type: DRUG; Name: doxorubicin; Assigned to Arm(s): doxorubicin
C: Arm Label: Aflibercept 2.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) | Arm Label: Aflibercept 4.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) | Intervention Type: DRUG; Name: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept 4.0 mg/kg | Intervention Type: DRUG; Name: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept 2.0 mg/kg
D: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: docetaxel, Drug: vandetanib | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Drug: docetaxel, Drug: vandetanib | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: vandetanib; Assigned to Arm(s): Arm I, Arm II

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Parallel Group, Open-label, Active Controlled, Multicenter Phase III Trial of Patupilone (EPO906) Versus Pegylated Liposomal Doxorubicin in Taxane/Platinum Refractory/Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian or Primary Peritoneal Cancer
Brief Summary: The objective of this study is to assess the safety and efficacy of patupilone compared to pegylated liposomal doxorubicin. Additionally, this study will assess the ability of patupilone to extend the survival time and potential beneficial effects in women who have nonresponsive or recurrent ovarian, primary fallopian, or primary peritoneal cancer.


Options:
A: Arm Label: gemcitabine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemcitabine | Arm Label: Gemcitabine + pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Gemcitabine, Drug: pazopanib | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Gemcitabine + pazopanib, gemcitabine | Intervention Type: DRUG; Name: pazopanib; Assigned to Arm(s): Gemcitabine + pazopanib
B: Arm Label: PLD 40 mg/m2 plus VTX-2337; Type: EXPERIMENTAL; Interventions: Drug: pegylated liposomal doxorubicin (PLD), Drug: VTX-2337 | Arm Label: PLD 40 mg/m2 plus placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: pegylated liposomal doxorubicin (PLD), Drug: Placebo | Intervention Type: DRUG; Name: pegylated liposomal doxorubicin (PLD); Assigned to Arm(s): PLD 40 mg/m2 plus VTX-2337, PLD 40 mg/m2 plus placebo | Intervention Type: DRUG; Name: VTX-2337; Assigned to Arm(s): PLD 40 mg/m2 plus VTX-2337 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): PLD 40 mg/m2 plus placebo
C: Arm Label: Patupilone; Type: EXPERIMENTAL; Interventions: Drug: EPO906 (Patupilone) | Arm Label: doxorubicin; Type: ACTIVE_COMPARATOR; Interventions: Drug: doxorubicin | Intervention Type: DRUG; Name: EPO906 (Patupilone); Assigned to Arm(s): Patupilone | Intervention Type: DRUG; Name: doxorubicin; Assigned to Arm(s): doxorubicin
D: Arm Label: Olaparib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib | Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Olaparib | Intervention Type: DRUG; Name: carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly; Assigned to Arm(s): Chemotherapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Parallel Group, Open-label, Active Controlled, Multicenter Phase III Trial of Patupilone (EPO906) Versus Pegylated Liposomal Doxorubicin in Taxane/Platinum Refractory/Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian or Primary Peritoneal Cancer
Brief Summary: The objective of this study is to assess the safety and efficacy of patupilone compared to pegylated liposomal doxorubicin. Additionally, this study will assess the ability of patupilone to extend the survival time and potential beneficial effects in women who have nonresponsive or recurrent ovarian, primary fallopian, or primary peritoneal cancer.


Options:
A: Arm Label: DOXIL + trabectedin; Type: EXPERIMENTAL; Interventions: Drug: Trabectedin, Drug: DOXIL, Drug: Dexamethasone | Arm Label: DOXIL; Type: ACTIVE_COMPARATOR; Interventions: Drug: DOXIL | Intervention Type: DRUG; Name: Trabectedin; Assigned to Arm(s): DOXIL + trabectedin | Intervention Type: DRUG; Name: DOXIL; Assigned to Arm(s): DOXIL, DOXIL + trabectedin | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): DOXIL + trabectedin
B: Arm Label: Patupilone; Type: EXPERIMENTAL; Interventions: Drug: EPO906 (Patupilone) | Arm Label: doxorubicin; Type: ACTIVE_COMPARATOR; Interventions: Drug: doxorubicin | Intervention Type: DRUG; Name: EPO906 (Patupilone); Assigned to Arm(s): Patupilone | Intervention Type: DRUG; Name: doxorubicin; Assigned to Arm(s): doxorubicin
C: Arm Label: Telcyta + Liposomal Doxorubicin; Type: EXPERIMENTAL; Interventions: Drug: Telcyta, Drug: Liposomal Doxorubicin | Arm Label: Liposomal Doxorubicin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liposomal Doxorubicin | Intervention Type: DRUG; Name: Telcyta; Assigned to Arm(s): Telcyta + Liposomal Doxorubicin | Intervention Type: DRUG; Name: Liposomal Doxorubicin; Assigned to Arm(s): Liposomal Doxorubicin, Telcyta + Liposomal Doxorubicin
D: Arm Label: Vintafolide + PLD; Type: EXPERIMENTAL; Interventions: Drug: Vintafolide, Drug: pegylated liposomal doxorubicin (PLD), Other: EC20 | Arm Label: PLD Alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: pegylated liposomal doxorubicin (PLD), Other: EC20 | Intervention Type: DRUG; Name: Vintafolide; Assigned to Arm(s): Vintafolide + PLD | Intervention Type: DRUG; Name: pegylated liposomal doxorubicin (PLD); Assigned to Arm(s): PLD Alone, Vintafolide + PLD | Intervention Type: OTHER; Name: EC20; Assigned to Arm(s): PLD Alone, Vintafolide + PLD

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Multinational, Multicenter, Double-blind, Placebo-controlled, Two-arm Parallel Group Trial of Rimonabant 20 mg OD for Reducing the Risk of Major Cardiovascular Events in Abdominally Obese Patients With Clustering Risk Factors
Brief Summary: The primary objective is to show whether rimonabant reduces the risk of a heart attack (MI), stroke, or death from an MI or stroke in patients with abdominal obesity with other cardiovascular (CV) risk factors.

The secondary objective is to show whether rimonabant reduces the risk of MI, stroke, CV death, or CV hospitalization in these patients.


Options:
A: Arm Label: Liraglutide; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Rimonabant; Type: EXPERIMENTAL; Interventions: Drug: Rimonabant | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for Rimonabant) | Intervention Type: DRUG; Name: Rimonabant; Assigned to Arm(s): Rimonabant | Intervention Type: DRUG; Name: Placebo (for Rimonabant); Assigned to Arm(s): Placebo
C: Arm Label: Lorcaserin 10 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Lorcaserin 10 mg once daily (QD) | Arm Label: Lorcaserin 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: Lorcaserin 10 mg twice a day (BID) | Arm Label: Matching Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching Placebo | Intervention Type: DRUG; Name: Lorcaserin 10 mg once daily (QD); Assigned to Arm(s): Lorcaserin 10 mg QD | Intervention Type: DRUG; Name: Lorcaserin 10 mg twice a day (BID); Assigned to Arm(s): Lorcaserin 10 mg BID | Intervention Type: DRUG; Name: Matching Placebo; Assigned to Arm(s): Matching Placebo
D: Arm Label: Rimonabant; Type: EXPERIMENTAL; Interventions: Drug: Rimonabant | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for Rimonabant) | Intervention Type: DRUG; Name: Rimonabant; Assigned to Arm(s): Rimonabant | Intervention Type: DRUG; Name: Placebo (for Rimonabant); Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of a Primary Health Care Intervention for the Prevention of Cardiovascular Disease in Rural Andhra Pradesh
Brief Summary: This study will evaluate the effectiveness of a novel cardiovascular disease prevention program designed for delivery through existing primary health care services in rural villages in Andhra Pradesh.

The primary aim is to increase the number of high-risk individuals in the population that are appropriately managed with proven, low-cost preventive interventions. The corresponding null hypothesis is therefore that the prevention program will result in no change in the proportion of high-risk individuals identified and treated in villages assigned to intervention compared with those villages assigned to control.


Options:
A: Arm Label: Memory Training Program; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Healthy Lifestyle Training Program; Type: EXPERIMENTAL; Interventions: Behavioral: Healthy Lifestyle Training Program | Intervention Type: BEHAVIORAL; Name: Healthy Lifestyle Training Program; Assigned to Arm(s): Healthy Lifestyle Training Program
B: Arm Label: Algorithm-based care; Type: OTHER; Interventions: Drug: ASA, Atenolol, hydrochlorothiazide, ACE inhibitor, Statin | Arm Label: Health-promotion; Type: OTHER; Interventions: Behavioral: Health Promotion | Intervention Type: DRUG; Name: ASA, Atenolol, hydrochlorothiazide, ACE inhibitor, Statin; Assigned to Arm(s): Algorithm-based care | Intervention Type: BEHAVIORAL; Name: Health Promotion; Assigned to Arm(s): Health-promotion
C: Arm Label: Immediate Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: risk reduction | Arm Label: Delayed Intervention; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: risk reduction | Intervention Type: BEHAVIORAL; Name: risk reduction; Assigned to Arm(s): Delayed Intervention, Immediate Intervention
D: Arm Label: Intensive pharmacist case management; Type: EXPERIMENTAL; Interventions: Drug: Antihypertensive agents and lipid lowering therapy | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: DRUG; Name: Antihypertensive agents and lipid lowering therapy; Assigned to Arm(s): Intensive pharmacist case management | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of a Primary Health Care Intervention for the Prevention of Cardiovascular Disease in Rural Andhra Pradesh
Brief Summary: This study will evaluate the effectiveness of a novel cardiovascular disease prevention program designed for delivery through existing primary health care services in rural villages in Andhra Pradesh.

The primary aim is to increase the number of high-risk individuals in the population that are appropriately managed with proven, low-cost preventive interventions. The corresponding null hypothesis is therefore that the prevention program will result in no change in the proportion of high-risk individuals identified and treated in villages assigned to intervention compared with those villages assigned to control.


Options:
A: Intervention Type: BEHAVIORAL; Name: UNITED Planned Care; Assigned to Arm(s): N/A
B: Arm Label: EDUCORE intervention; Type: EXPERIMENTAL; Interventions: Behavioral: EDUCORE intervention | Arm Label: control group; Type: ACTIVE_COMPARATOR; Interventions: Other: Control group | Intervention Type: BEHAVIORAL; Name: EDUCORE intervention; Assigned to Arm(s): EDUCORE intervention | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): control group
C: Arm Label: Algorithm-based care; Type: OTHER; Interventions: Drug: ASA, Atenolol, hydrochlorothiazide, ACE inhibitor, Statin | Arm Label: Health-promotion; Type: OTHER; Interventions: Behavioral: Health Promotion | Intervention Type: DRUG; Name: ASA, Atenolol, hydrochlorothiazide, ACE inhibitor, Statin; Assigned to Arm(s): Algorithm-based care | Intervention Type: BEHAVIORAL; Name: Health Promotion; Assigned to Arm(s): Health-promotion
D: Arm Label: Intervention; Type: OTHER; Interventions: Behavioral: Vascular Management Program, Behavioral: Clinical Care Coordinators, Behavioral: Web-based Vascular Tracker for Patient and Physician, Behavioral: Automated Telephone Reminder System | Intervention Type: BEHAVIORAL; Name: Vascular Management Program; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Clinical Care Coordinators; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Web-based Vascular Tracker for Patient and Physician; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Automated Telephone Reminder System; Assigned to Arm(s): Intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Psychosoziale Intervention Zur Reduktion Diabetischer Spätschäden Bei Diabetes Mellitus Typ 2
Brief Summary: The purpose of this study is to determine whether a structured stress relief management program can prevent the progression of late diabetic complications in patients with type 2 diabetes.


Options:
A: Intervention Type: BEHAVIORAL; Name: Mindfulness Based Stress Reduction; Assigned to Arm(s): N/A
B: Arm Label: Distress management; Type: EXPERIMENTAL; Interventions: Behavioral: A cognitive behavior therapy distress management program targeting wellbeing in patients with atrial fibrillation and their relatives | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: A cognitive behavior therapy distress management program targeting wellbeing in patients with atrial fibrillation and their relatives; Assigned to Arm(s): Distress management
C: Arm Label: Cardiac Rehabilitation plus Transcendental Meditation; Type: EXPERIMENTAL; Interventions: Behavioral: Cardiac Rehabilitation plus Transcendental Meditation | Arm Label: Cardiac Rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cardiac Rehabilitation plus Transcendental Meditation | Intervention Type: BEHAVIORAL; Name: Cardiac Rehabilitation plus Transcendental Meditation; Assigned to Arm(s): Cardiac Rehabilitation, Cardiac Rehabilitation plus Transcendental Meditation
D: Arm Label: Kg-Free; Type: EXPERIMENTAL; Interventions: Behavioral: Kg-Free, Other: Treatment as Usual | Arm Label: Treatment as Usual (TAU); Type: OTHER; Interventions: Other: Treatment as Usual | Intervention Type: BEHAVIORAL; Name: Kg-Free; Assigned to Arm(s): Kg-Free | Intervention Type: OTHER; Name: Treatment as Usual; Assigned to Arm(s): Kg-Free, Treatment as Usual (TAU)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Psychosoziale Intervention Zur Reduktion Diabetischer Spätschäden Bei Diabetes Mellitus Typ 2
Brief Summary: The purpose of this study is to determine whether a structured stress relief management program can prevent the progression of late diabetic complications in patients with type 2 diabetes.


Options:
A: Arm Label: Pharmacist intervention; Type: EXPERIMENTAL; Interventions: Other: Pharmacist based QI program | Arm Label: Control - usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: Pharmacist based QI program; Assigned to Arm(s): Pharmacist intervention | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Control - usual care
B: Intervention Type: BEHAVIORAL; Name: Mindfulness Based Stress Reduction; Assigned to Arm(s): N/A
C: Arm Label: ATSM + Health Coach and CKD Registry; Type: EXPERIMENTAL; Interventions: Behavioral: CKD Registry, Behavioral: ATSM + Health Coach | Arm Label: CKD Registry; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CKD Registry | Arm Label: ATSM + Health Coach; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: ATSM + Health Coach | Arm Label: Usual Care (no interventions); Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: CKD Registry; Assigned to Arm(s): ATSM + Health Coach and CKD Registry, CKD Registry | Intervention Type: BEHAVIORAL; Name: ATSM + Health Coach; Assigned to Arm(s): ATSM + Health Coach, ATSM + Health Coach and CKD Registry | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Usual Care (no interventions)
D: Arm Label: Inform Me: web-based education tool; Type: EXPERIMENTAL; Interventions: Behavioral: Inform Me: web-based education tool | Arm Label: Control Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Inform Me: web-based education tool; Assigned to Arm(s): Inform Me: web-based education tool

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 2 Study of the Effect of 7-Methylxanthine on the Progression of Childhood Myopia
Brief Summary: 7-methylxanthine has been shown to increase the concentration and thickness of collagen fibrils in rabbit sclera. Deficient collagen in the sclera may be the cause of progression of childhood myopia. The study hypothesis is that treatment with 7-methylxanthine will stabilize the sclera and prevent further progression of myopia.


Options:
A: Intervention Type: DRUG; Name: 7-methylxanthine; Assigned to Arm(s): N/A
B: Intervention Type: DEVICE; Name: Bifocal Spectacle Lenses; Assigned to Arm(s): N/A
C: Arm Label: Test lens C; Type: EXPERIMENTAL; Interventions: Device: 1 Day Acuvue Moist | Arm Label: Test lens A; Type: ACTIVE_COMPARATOR; Interventions: Device: 1 Day Acuvue Moist | Intervention Type: DEVICE; Name: 1 Day Acuvue Moist; Assigned to Arm(s): Test lens A, Test lens C
D: N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Reactogenicity and Immunogenicity of Three Doses of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine
Brief Summary: The aim of this study is to evaluate the reactogenicity, safety and immunogenicity of GSK Biologicals' human rotavirus (HRV) vaccine given concomitantly with routine vaccines including OPV in HIV positive infants. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.


Options:
A: Arm Label: Rotarix 3-Dose Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™ | Arm Label: Rotarix 2-Dose Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™, Biological: Placebo | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Rotarix™; Assigned to Arm(s): Rotarix 2-Dose Group, Rotarix 3-Dose Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group, Rotarix 2-Dose Group
B: Arm Label: Rotarix Group; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' liquid human rotavirus vaccine 444563, Biological: Infanrix™, Biological: Institute of Medical Biology Chinese Academy of Medical Sciences' Oral poliovirus vaccine (OPV) | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: Infanrix™, Biological: Institute of Medical Biology Chinese Academy of Medical Sciences' Oral poliovirus vaccine (OPV) | Intervention Type: BIOLOGICAL; Name: GSK Biologicals' liquid human rotavirus vaccine 444563; Assigned to Arm(s): Rotarix Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group | Intervention Type: BIOLOGICAL; Name: Infanrix™; Assigned to Arm(s): Placebo Group, Rotarix Group | Intervention Type: BIOLOGICAL; Name: Institute of Medical Biology Chinese Academy of Medical Sciences' Oral poliovirus vaccine (OPV); Assigned to Arm(s): Placebo Group, Rotarix Group
C: Arm Label: Rotarix Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix, Biological: Tritanrix-HB+Hib, Biological: Polio Sabin | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: Tritanrix-HB+Hib, Biological: Polio Sabin | Intervention Type: BIOLOGICAL; Name: Rotarix; Assigned to Arm(s): Rotarix Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group | Intervention Type: BIOLOGICAL; Name: Tritanrix-HB+Hib; Assigned to Arm(s): Placebo Group, Rotarix Group | Intervention Type: BIOLOGICAL; Name: Polio Sabin; Assigned to Arm(s): Placebo Group, Rotarix Group
D: Intervention Type: BIOLOGICAL; Name: 2-dose oral live attenuated G1P[8] human rotavirus vaccine; Assigned to Arm(s): N/A

Answer: C